Perinatal EvidenceCompass
Prepopulated workbenchMED-056

Mood stabilizers/antiseizure — core

Lithium carbonate

Core mood stabilizer/antiseizure medication; psychiatric and epilepsy indications must be separated

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Lithium carbonate
Entity type
single-ingredient drug
Active component(s)
Lithium carbonate
Formulation / route / interval
Oral immediate- or extended-release tablet/capsule
Attachment entry
Lithium carbonate
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Distinct salt/formulation from lithium citrate; report lithium exposure consistently; Also: antidepressant augmentation and bipolar maintenance
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

7 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

B-001Provisional public source

First-trimester lithium exposure was associated with a modestly increased cardiac-malformation risk in a large adjusted US cohort.

Public-source certainty descriptor
moderate—large observational cohort
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
no lithium exposure
Effect or numbers carried forward

Cardiac malformations: 16/663 lithium-exposed infants (2.41%) versus 15,251/1,322,955 unexposed infants (1.15%); adjusted RR 1.65 (95% CI 1.02–2.68). The crude absolute difference is about 1.26 percentage points and is not a causal NNH.

Limitations

Residual confounding, prescription-fill exposure, and low counts for specific cardiac defects.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-002Provisional public source

The lithium cardiac-malformation association was dose related in the primary cohort.

Public-source certainty descriptor
low-to-moderate—observational dose strata
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
no lithium exposure
Effect or numbers carried forward

RR 1.11 at ≤600 mg/day; 1.60 at 601–900 mg/day; 3.22 at >900 mg/day

Limitations

Wide confidence intervals, prescribed rather than ingested dose, and possible severity confounding.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-003Provisional public source

Lithium clearance rises during pregnancy and falls rapidly after birth, requiring concentration-guided pregnancy and postpartum management.

Public-source certainty descriptor
moderate for direction; low for exact schedule
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy through early postpartum
Comparator
prepregnancy personal baseline
Effect or numbers carried forward

Personal trough monitoring; observational authors proposed weekly checks from 34 weeks and twice weekly for the first 2 postpartum weeks

Limitations

Exact monitoring schedule is not trial validated and must respond to renal function, illness, and interactions.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-004Provisional public source

Routine lithium dose reduction or discontinuation before delivery is controversial rather than settled.

Public-source certainty descriptor
very low—small nonrandomized study
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
labor and delivery
Comparator
lowered/held versus continued exposure
Effect or numbers carried forward

Small observational cohort found no neonatal-outcome association with delivery lithium concentration and recommended against routine lowering

Limitations

Small sample, nonrandomized management, and limited power for rare toxicity; ACOG notes some experts still hold before labor/scheduled delivery.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-005Provisional public source

Breastfeeding during lithium treatment is a conditional, monitoring-intensive option because infant exposure is highly variable.

Public-source certainty descriptor
low—case series and pharmacokinetic reports
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
lactation, especially newborn period
Comparator
no breast-milk lithium exposure
Effect or numbers carried forward

No single reliable relative infant dose; maternal milk and infant serum vary widely

Limitations

Selection of healthy term infants and heterogeneous infant lithium/renal/thyroid monitoring.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-032Provisional public source

ACOG recommends against discontinuing mood stabilizers during pregnancy solely because of pregnancy, except that valproate should be avoided when possible.

Public-source certainty descriptor
guideline recommendation
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy
Comparator
discontinuation
Effect or numbers carried forward

Strong recommendation; moderate-quality evidence in ACOG for continuation except valproate

Limitations

Not a mandate to continue every ineffective or unsafe regimen; indication and relapse history remain decisive.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-063Provisional public source

A stable patient should not be switched reflexively after conception solely to use a medicine with more pregnancy data.

Public-source certainty descriptor
guideline recommendation
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
after conception
Comparator
continuing an effective regimen
Effect or numbers carried forward

No single effect estimate; relapse and fetal polypharmacy tradeoff

Limitations

Important exceptions include valproate and compelling toxicity/ineffectiveness; individual history controls the decision.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending